Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3559685 Target Snapshot

RAF serine/threonine protein kinase · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2Compounds
1Assays
0Approved Drugs
2.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

RAF serine/threonine protein kinase shows approved-linked disease relevance led by low grade glioma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P04049. Start with low grade glioma, then reuse UniProt P04049 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with low grade glioma, then reuse UniProt P04049 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
low grade glioma

RAF serine/threonine protein kinase shows approved-linked disease relevance led by low grade glioma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with low grade glioma because it currently carries approved-linked support. Linked drugs include TOVORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Protein anchor
RAF proto-oncogene serine/threonine-protein kinase

RAF proto-oncogene serine/threonine-protein kinase

Review this target as RAF serine/threonine protein kinase, mapped to UniProt P04049. ChEMBL maps the protein component as RAF proto-oncogene serine/threonine-protein kinase. Sequence length is 648 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P04049 Protein 648 aa
Open protein block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats RAF serine/threonine protein kinase as ChEMBL target CHEMBL3559685, mapped to UniProt P04049. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
RAF serine/threonine protein kinase
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3559685
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04049
RAF proto-oncogene serine/threonine-protein kinase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether RAF serine/threonine protein kinase is the right protein anchor across sources, using UniProt P04049 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why low grade glioma is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameRAF serine/threonine protein kinase
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP04049
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRAF proto-oncogene serine/threonine-protein kinase
UniProt AccessionP04049
Component TypeProtein
Sequence Length648 aa

RAF proto-oncogene serine/threonine-protein kinase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as RAF serine/threonine protein kinase, mapped to UniProt P04049. ChEMBL maps the protein component as RAF proto-oncogene serine/threonine-protein kinase. Sequence length is 648 aa.

Mapped IDP04049
Review nameRAF serine/threonine protein kinase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

RAF serine/threonine protein kinase shows approved-linked disease relevance led by low grade glioma. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
low grade glioma
1 linked drug · 1 direct · 1 efficacy
Linked drugTOVORAFENIB
Clinical signal Phase II
cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugBELVARAFENIB
Linked drugTOVORAFENIB
Clinical signal Phase II
neoplasm
2 linked drugs · 2 direct · 2 efficacy
Linked drugBELVARAFENIB
Linked drugTOVORAFENIB
Clinical signal Phase II
Craniopharyngioma
1 linked drug · 1 direct · 1 efficacy
Linked drugTOVORAFENIB
Clinical signal Phase II
Langerhans Cell Histiocytosis
1 linked drug · 1 direct · 1 efficacy
Linked drugTOVORAFENIB
Clinical signal Phase I
melanoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugBELVARAFENIB
Linked drugTOVORAFENIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with low grade glioma because it currently carries approved-linked support. Linked drugs include TOVORAFENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaselow grade glioma
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC502.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3934468 6.0 IC50 1000.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
0
5.5
1
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

1
Total Assays
1
Tested Compounds
1
Assay Types
Binding — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 1 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine